JP2023506732A5 - - Google Patents

Info

Publication number
JP2023506732A5
JP2023506732A5 JP2022535060A JP2022535060A JP2023506732A5 JP 2023506732 A5 JP2023506732 A5 JP 2023506732A5 JP 2022535060 A JP2022535060 A JP 2022535060A JP 2022535060 A JP2022535060 A JP 2022535060A JP 2023506732 A5 JP2023506732 A5 JP 2023506732A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antigen
binding fragment
antibody
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/064324 external-priority patent/WO2021119321A1/en
Publication of JP2023506732A publication Critical patent/JP2023506732A/ja
Publication of JP2023506732A5 publication Critical patent/JP2023506732A5/ja
Pending legal-status Critical Current

Links

JP2022535060A 2019-12-10 2020-12-10 ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用 Pending JP2023506732A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962946268P 2019-12-10 2019-12-10
US62/946,268 2019-12-10
US202062987148P 2020-03-09 2020-03-09
US62/987,148 2020-03-09
PCT/US2020/064324 WO2021119321A1 (en) 2019-12-10 2020-12-10 Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia

Publications (2)

Publication Number Publication Date
JP2023506732A JP2023506732A (ja) 2023-02-20
JP2023506732A5 true JP2023506732A5 (https=) 2023-12-18

Family

ID=74175938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535060A Pending JP2023506732A (ja) 2019-12-10 2020-12-10 ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用

Country Status (10)

Country Link
US (1) US20230272112A1 (https=)
EP (1) EP4072672A1 (https=)
JP (1) JP2023506732A (https=)
KR (1) KR20220125249A (https=)
CN (1) CN115066272A (https=)
AU (1) AU2020402044A1 (https=)
CA (1) CA3161347A1 (https=)
IL (1) IL293617A (https=)
MX (1) MX2022007071A (https=)
WO (1) WO2021119321A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI682780B (zh) * 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
US20150004174A1 (en) * 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
ES2914978T3 (es) * 2013-10-11 2022-06-20 Sanofi Biotechnology Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
PT3689913T (pt) * 2014-10-09 2022-06-20 Regeneron Pharma Uso de um inibidor de pcsk9 para tratar a hiperlipidemia
HK1257556A1 (zh) * 2016-02-26 2019-10-25 耀石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗

Similar Documents

Publication Publication Date Title
US20240261400A1 (en) Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US20230000976A1 (en) Methods for treating patients with familial hypercholesterolemia
ES2914978T3 (es) Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
JP2022000443A5 (https=)
JP2022133396A5 (https=)
IL277127B1 (en) Using pcsk9 tracking to reduce cardiovascular risk
JP2016538277A5 (https=)
RU2016142277A (ru) Антитела человека к pcsk9 для применения в способах лечения конкретных групп индивидуумов
JP2017522316A5 (https=)
RU2017104799A (ru) Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
JP2017506626A (ja) 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法
JP2017528427A5 (https=)
JP2016522211A5 (https=)
JP2017506626A5 (https=)
JP2022078306A (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法
FI3416684T3 (fi) Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria
JP2019512472A5 (https=)
US20240197870A1 (en) Methods for treating patients with refractory hypercholesterolemia
JP2023506732A5 (https=)
JP2020143156A (ja) 心血管リスクを低減させる方法
ES2779126T3 (es) Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
EP4122493A1 (en) Method for treating cholesterol-related diseases
JP2020183439A5 (https=)
Imai et al. Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan
Eikkula Developing orally bioavailable PCSK9-inhibitors